Sanofi Plavix Inventory Rise Expected After Significant Q1 Destocking
Sanofi-Synthelabo expects wholesale levels of Plavix (clopidogrel) to climb following a "very large" destocking of the antithrombotic during the first quarter of 2003
You may also be interested in...
Bristol's revised approach to accounting for excess inventory leaves the company room to offer trade incentives in the future
Sanofi-Synthelabo Eloxatin first-line data in advanced colonic and rectal adenocarcinoma will be submitted to FDA by the third quarter of 2003, following oxaliplatin's approval as second-line use
Bristol-Myers Squibb is turning to Exec VP Donald Hayden to restore the performance of - and confidence in - its U.S. pharmaceutical business